Edition:
United States

Supernus Pharmaceuticals Inc (SUPN.OQ)

SUPN.OQ on NASDAQ Stock Exchange Global Market

37.99USD
12:17pm EST
Change (% chg)

$-1.11 (-2.84%)
Prev Close
$39.10
Open
$39.03
Day's High
$39.05
Day's Low
$37.97
Volume
53,880
Avg. Vol
208,706
52-wk High
$61.25
52-wk Low
$30.16

Select another date:

Thu, Dec 20 2018

Supernus Pharma's ADHD drug meets main goal in study on adolescents

Supernus Pharmaceuticals Inc said on Thursday its drug for attention deficit hyperactivity disorder met the main goal in a late-stage trial on adolescents, weeks after results from trials testing the drug on children failed to impress investors.

UPDATE 2-Supernus Pharma's ADHD drug meets main goal in study on adolescents

Dec 20 Supernus Pharmaceuticals Inc said on Thursday its drug for attention deficit hyperactivity disorder met the main goal in a late-stage trial on adolescents, weeks after results from trials testing the drug on children failed to impress investors.

Supernus Pharma's ADHD drug meets main goal in late-stage trial

Dec 20 Supernus Pharmaceuticals Inc said on Thursday its drug for attention deficit hyperactivity disorder met the main goal in a late-stage study testing in adolescents.

Supernus Pharma's ADHD treatment fails to impress; shares fall

Supernus Pharmaceuticals Inc's treatment for attention deficit hyperactivity disorder met the main goal of two trials, but shares fell about 16 percent on Thursday as the data failed to convince some investors that the drug was better than rivals.

UPDATE 3-Supernus Pharma's ADHD treatment fails to impress; shares fall

Dec 6 Supernus Pharmaceuticals Inc's treatment for attention deficit hyperactivity disorder met the main goal of two trials, but shares fell about 16 percent on Thursday as the data failed to convince some investors that the drug was better than rivals.

Supernus Pharma's ADHD treatment succeeds in two late-stage studies

Dec 6 Supernus Pharmaceuticals Inc on Thursday said its experimental treatment for attention deficit hyperactivity disorder (ADHD) met the main goal of reducing disorder symptoms in children in two late-stage studies.

Select another date: